Therapeutic Focus
Onconova is focused on discovering and developing novel products for patients with cancer.
About Onconova Therapeutics
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
Onconova’s novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and a dose-escalation and expansion Phase 1 trial is planned in the U.S. to commence in the first half of 2021. Onconova’s product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with advanced KRAS+ lung adenocarcinoma in combination with nivolumab.
Onconova Therapeutics was incorporated in 1998 in Delaware and began trading on the NASDAQ stock exchange under the ticker symbol ONTX in July, 2013.
Onconova Therapeutics News Releases
- Onconova Therapeutics to Participate in Three Investment Conferences During the Month of March March 1, 2021
- Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement February 24, 2021
- Onconova Therapeutics, Inc. Announces Closing of $28.75 Million Public Offering of Common Stock Including Full Exercise of the Over-Allotment Option February 16, 2021
- Onconova Therapeutics to Present Corporate Update at the 2021 BIO CEO & Investor Digital Conference February 16, 2021
- Onconova Therapeutics, Inc. Announces Pricing of $25 Million Public Offering of Common Stock February 11, 2021
- Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock February 10, 2021
